Page 19 - Diagnostics Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Commenting on the Group’s performance in the first quarter, Roche CEO Severin Schwan said: “In 2021, Roche remains strongly committed to the fight against COVID-19. The uptake of our recently introduced diagnostic tests and medicines remains strong, while we continue to see the expected impact from biosimilars on sales of our established medicines. Our broad product pipeline keeps making good progress. I am particularly pleased about the highly encouraging study results of our immunotherapy Tecentriq in early lung cancer and of faricimab in ophthalmology. The upcoming acquisition of GenMa...

Group sales increase 3% 1 at constant exchange rates (CER); 1% decline in Swiss francs, as a result of the appreciation of the Swiss franc Pharmaceuticals Division sales: As expected, significant impact from biosimilars (CHF -1.6 billion) Base effect from the strong first quarter 2020 (negative impact of the pandemic only since April 2020) Overall, this results in a 9% decline in sales. Diagnostics Division sales: Roche's contributions to the fight against the COVID-19 pandemic in the first quarter: SARS-CoV-2 Rapid Antigen Test Nasal to...

Roche Stock Up On Higher Q1 Sales At Constant Rates; Backs FY21 Outlook SOUTH SAN FRANCISCO (dpa-AFX) - Shares of Roche were gaining around 2 percent in Swiss trading after the drug major reported Wednesday a 3 percent rise in first-quarter sales at constant currency basis mainly driven by strong growth in Diagnostics Division. Sales, on a reported basis, edged down 1 percent mainly with significant impact from biosimilars. Looking ahead for fiscal 2021, the company continues to expect sales to grow in the low- to mid-single digit range, at constant exchange rates, despite the continued stron...

  Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.   The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the r...

Investegate announcements from Avacta Group PLC, Electronic Communications with Shareholders